α-Eleostearic Acid as a Senolytic Therapy

Created on 11/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

α-Eleostearic acid, a fatty acid from bitter melon and tung tree seeds, is studied to clear worn-out cells that build up with age by driving oxidation of their own membranes. Its cell-clearing evidence comes only from cell and mouse work by one group with a financial interest. No person has knowingly taken the purified compound in a published study, and human data on related forms carry signals of harm. (Full Review)

Protocol

Published animal regimen, acute
50 mg/kg once daily, 5 days
α-ESA or its methyl ester, administered orally by stomach tube, in 20-to-22-month and 32-month-old mice
Only human exposure regimen on record
4.5 g/day bitter melon seed oil
About 2.3 g/day of α-ESA, three capsules after each meal for 12 weeks; weight endpoint, no results posted
No validated human-equivalent dose
Roughly 300 mg/day at 70 kg
Body-surface-area scaling of the mouse dose in reader comments; no human study of absorption or blood levels tests it
Time to effect
Waist circumference
Two months
Eggs enriched with related fats, not α-ESA; body fat did not differ
Senescence and inflammatory-signal gene expression
Within two days
Of a five-day course, in mice; unknown in humans
Functional scores
Over six weeks
In mice; unknown in humans

Benefits

Contraindications
  • Hereditary haemochromatosis or any iron overload (serum ferritin above roughly 1,000 µg/L, or transferrin saturation above 45%)
  • Advanced chronic kidney disease (eGFR below 15 mL/min/1.73 m², or dialysis)
  • G6PD deficiency
  • Pregnancy, lactation, and anyone below adult age
  • Anyone using crude tung oil or tung seeds as a source
Key Interactions
Theoretical (inferred from mechanism)
  • Vitamin E and tocotrienols (α-tocopherol, α-tocotrienol)
  • Iron salts and iron-absorption enhancers (ferrous sulfate, high-dose ascorbic acid)
  • Iron chelators (deferoxamine, deferasirox)
  • Selenium-dependent antioxidant capacity (selenomethionine, sodium selenite)
  • Long-chain omega-3 supplements (fish oil, krill oil)
  • Conjugated linoleic acid supplements and pomegranate seed oil (punicic acid)
  • Glucose-lowering drugs (metformin, insulin)
  • Vitamin K antagonists (warfarin, acenocoumarol)
  • Other senolytics and ferroptosis inducers (dasatinib plus quercetin, sulfasalazine)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Reduced Insulin Sensitivity and Raised Fasting Glucose; Raised Aspartate Aminotransferase; Gastrointestinal Toxicity of Crude α-ESA-Rich Seeds and Oil; Neurological Illness Linked to an α-ESA-Containing Mushroom
  • Speculative: Increased Systemic Lipid Peroxidation; Depletion of Tissue Omega-3 Fatty Acids; Off-Target Ferroptosis in Iron-Rich or Antioxidant-Poor Tissue

Monitoring

Marker Target Why
Serum ferritin 30–300 µg/L in men, 15–200 µg/L in women Safety check: high iron amplifies the mechanism
Transferrin saturation 20–50% Safety check: circulating iron that drives membrane oxidation
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ALT 7–55 IU/L, AST 8–48 IU/L Safety check: AST rose slightly in conjugated linoleic acid trials
Fasting glucose 70–99 mg/dL Safety check: rose in conjugated linoleic acid trials
Full blood count (haemoglobin, red-cell indices) Haemoglobin 13.2–16.6 g/dL in men, 11.6–15.0 g/dL in women Safety check: a falling haemoglobin signals red-cell destruction
Urinary 8-iso-prostaglandin F2α No established target; track change from the individual's own baseline Marks whole-body lipid peroxidation
Interleukin-6 (IL-6) No established target; track change from the individual's own baseline Senescent-cell inflammatory signal

Cadence: Baseline iron panel with ferritin and transferrin saturation, liver enzymes, fasting glucose and full blood count before any exposure; liver enzymes and fasting glucose at the end of each course and again four weeks later; iron panel every six to twelve months.

Qualitative Assessment

  • Physical function (grip strength, walking pace, stair tolerance)
  • Joint and muscle discomfort
  • Energy and exercise recovery
  • Any new neurological symptom, particularly tremor, slurred speech or unsteadiness
  • Gastrointestinal tolerance